Searching...
17 results for “pharma research”
...to make new products. And then the FDA comes along, writes a lot of these, top pharma companies predate the FDA, and modern clinical development is formed. And so there's a three part type, component for all these businesses where there is manufactur
12:41 / 13:46
from transcript12:41 – 13:46
...Pharma's acquisitions that were coming from China were single digits. And I think in '25, it was between 3040% of their acquisitions. So this is a sea change in Big Pharma's sourcing strategy. And, you know, they have oriented more towards these Chin
20:22 / 21:27
from transcript20:22 – 21:27
...pharma is increasingly buying their new early stage assets out of China. And so, you know, go back five, six years. The percentage of Big Pharma's acquisitions that were coming from China were single digits.
19:33 / 20:37
from transcript19:33 – 20:37
...ago, large pharmaceutical companies, Merck, Pfizer, Eli Lilly, had these research and development groups and they would sit around and read up articles and do their own basic science and say, you know, I think we should do something to go after such
6:43 / 7:51
from transcript6:43 – 7:51
...pharma together. And some of those will get there through become being pharmas that acquire biotechs, and others will be
24:43 / 25:50
from transcript24:43 – 25:50
...major pharma licensing deals now involve Chinese companies. I think that's up from, like, almost zero five years ago. There are some interesting data to look at. Yep. So just to give you a couple stats, the API that's sourced into The US, I don't hav
15:44 / 16:45
from transcript15:44 – 16:45
...in pharma of doing exactly this. What is slightly next to the patent, but does basically the same thing. Yes. To your point, though, it is still quite scientifically difficult. It's not like software here. We're like, yeah. Yeah. Yeah. I write some c
47:56 / 49:06
from transcript47:56 – 49:06
...pharma through either acquisition or through a partnership. But the idea of a long duration clinical trial is a product of scale. You're recruiting tons and tons of people. And the reason you're doing that is to get enough statistical significance th
20:54 / 22:05
from transcript20:54 – 22:05
...pharma to take an idea or an asset, bring it to a value inflection point. You see some efficacy. You show it's safe. You have a compound. The compound seems like it makes sense, and then sell it to big pharma. They're not actually biotech isn't a com
28:30 / 29:31
from transcript28:30 – 29:31
...pharma companies have been so slow to adopt this? Because it's not canonically considered something you develop a drug for. Like, one of the biggest risks, when you guys invested, besides random chick, never done anything, besides, like, being associ
0:43 / 1:52
from transcript0:43 – 1:52
...is in m and a. I can talk a bit more about why that is, but the larger point here being that we want to be on that forefront.
33:33 / 34:52
from transcript33:33 – 34:52
...in the pharma context. Right? And I think that's just sort of the most important thing, in in in this industry. And so I think we believe in virtual cells, not just because we think it will be a fountain of fundamental mechanistic insights for discov
23:12 / 24:25
from transcript23:12 – 24:25
...Pharma kinda almost becomes like the enterprise software industry. Like, at the end of the day, there only are a few companies at scale that have the infrastructure and the go to market to operate. And, like, yes, you can build a big company on top o
1:18:44 / 1:19:48
from transcript1:18:44 – 1:19:48
...the pharma labs. Then you, try a drug in healthy subjects. That's called a phase one trial. Typically, a small number, a handful. And then you give the drug to subjects with the condition, and that's a phase two. It's a limited study. And then phase
13:29 / 14:30
from transcript13:29 – 14:30
...and pharma has has been a shrinking, in interest in certain the the rate of growth. What what's it gonna take for these, innovations in in in the science to reflect themselves in in business models and in in growth for the industry? A lot of these bi
22:25 / 23:35
from transcript22:25 – 23:35
...in our academic spaces. It's not just the pharma labs.
12:39 / 13:53
from transcript12:39 – 13:53
...pharma companies, and it created the so called CRO or contract research organization ecosystem. So you now, as a consequence of that, for the past twenty years, have had a very proficient environment full of, contract organizations that you can hire
19:30 / 20:33
from transcript19:30 – 20:33
Have a podcast?
Run your podcast through Clypt
Get ranked clips, hooks, and ready-to-post copy from your own episodes. Free to try.